UNIGE document Scientific Article
previous document  unige:31980  next document
add to browser collection


Published in Revue médicale suisse. 2011, vol. 7, no. 278, p. 138-144
Abstract Calcium supplements should be used according to the dietary intakes. Daily vitamin D supplements have beneficial on bone and extraskeletal effects. Denosumab is registered in Switzerland for the treatment of postmenopausal osteoporosis and to prevent bone loss induced by sex hormone deprivation therapies in men and women. Zoledronate has a long-term efficacy on bone resorption in postmenopausal women and prevents bone loss induced by sex hormone deprivation therapies in both sexes. Teriparatide exerts beneficial effects on maxillary bone. Odanacatib decreases bone resorption and increases bone mineral density. Cinacalcet could be used as long-term treatment in case of hyperparathyroidism. Adverse events associated with the use of bisphosphonate are still under discussion. Strontium ranelate will not be introduced in Switzerland.
Keywords Bone Density Conservation Agents/therapeutic useCalcium, Dietary/administration & dosageHumansOsteoporosis/prevention & controlVitamin D/therapeutic use
PMID: 21400947
Full text
Article (Published version) (584 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://rms.medhyg.ch/numero-278-page-138.htm
Research group Nutrition et os (66)
(ISO format)
UEBELHART, Brigitte Florence, RIZZOLI, René. Ostéoporose. In: Revue médicale suisse, 2011, vol. 7, n° 278, p. 138-144. https://archive-ouverte.unige.ch/unige:31980

361 hits

0 download


Deposited on : 2013-12-10

Export document
Format :
Citation style :